Beneficial effects of pharmacotherapy on weight loss, depressive symptoms, and eating patterns in obese binge eaters and non-binge eaters.

Simple item page
dc.contributor.authorAlger, S A
dc.contributor.authorMalone, M
dc.contributor.authorCerulli, J
dc.contributor.authorFein, S
dc.contributor.authorHoward, L
dc.date.accessioned2024-02-14T16:46:01Z
dc.date.available2024-02-14T16:46:01Z
dc.date.issued1999-09
dc.descriptionClick on the Resource Link to access the article (may not be free).
dc.description.abstractObjective: The purpose of this study was to compare the impact of drug therapy on weight loss, Beck Depression Inventory (BDI) scores, and binge eating patterns (BES) between obese binge eaters and non-binge eaters. Research methods and procedures: 22 severe binge eaters, 17 moderate binge eaters, and 16 non-binge eaters received phentermine resin 15mg/day and dl-fenfluramine 20mg three times daily over a 6 month period for weight loss. All data are reported as mean+/-S. Results: The percent weight loss compared to baseline within the 3 groups ranged from 8.9% to 11.3% at 3 months and 10.6% to 14.9% at 6 months. After 6 months, 73% of the severe binge eaters, 59% of moderate binge eaters and 69% of non-binge eaters had experienced more than 10% weight loss. BDI scores were significantly higher in the severe group at baseline when compared to non-binge eaters (p<0.006). After 3 and 6 months BDI scores improved in all groups but remained significantly different between the severe and non-binge eaters until the 6-month assessment. BES scores declined in all groups over the 6-month period. Echocardiograms were performed in 35 of 55 subjects following reports of a possible association between fenfluramine and valvular changes. Fifteen (43%) of subjects had no abnormal findings and 20 (57%) had evidence of valvular insufficiency occurring in one or more valves. Seven patients (20%) had significant valve damage according to the DHHS and FDA criteria. Conclusion: After 24 weeks of treatment severe binge eaters improved their eating pattern, depression scores, and achieved weight loss similar to non-binge eaters. These data suggest that pharmacologic intervention for weight loss and subsequent weight maintenance can be as successful in binge eaters as non-binge eaters. A relationship was seen between duration of drug treatment and valvular insufficiency in subjects treated for an average of 52 weeks. These findings validate the FDA requirement for studies of at least 1 year duration to evaluate both the safety and efficacy of pharmacologic treatment for obesity.
dc.description.urihttps://doi.org/10.1002/j.1550-8528.1999.tb00435.x
dc.identifier.citationAlger SA, Malone M, Cerulli J, Fein S, Howard L. Beneficial effects of pharmacotherapy on weight loss, depressive symptoms, and eating patterns in obese binge eaters and non-binge eaters. Obes Res. 1999 Sep;7(5):469-76. doi: 10.1002/j.1550-8528.1999.tb00435.x. PMID: 10509604.
dc.identifier.issn1071-7323
dc.identifier.other10509604
dc.identifier.urihttps://hdl.handle.net/20.500.14303/556
dc.language.isoen
dc.publisherNorth American Association for the Study of Obesity
dc.relation.ispartofObesity Research
dc.rightsThis Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). http://rightsstatements.org/vocab/InC/1.0/
dc.subjectAppetite Depressants / therapeutic use
dc.subjectDepression / drug therapy
dc.subjectEating / drug effects
dc.subjectFeeding and Eating Disorders / drug therapy
dc.subjectObesity / drug therapy
dc.subjectWeight Loss
dc.titleBeneficial effects of pharmacotherapy on weight loss, depressive symptoms, and eating patterns in obese binge eaters and non-binge eaters.
dc.typeArticle
local.departmentprogramDepartment of Pharmacy Practice
Files
Collections
Cerulli, Jennifer Publications